Avalo Therapeutics, Inc. $AVTX Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC grew its stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 556.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 120,114 shares of the company’s stock after buying an additional 101,814 shares during the period. Renaissance Technologies LLC owned 0.41% of Avalo Therapeutics worth $1,793,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Caligan Partners LP acquired a new position in Avalo Therapeutics in the third quarter valued at $10,592,000. Balyasny Asset Management L.P. purchased a new stake in Avalo Therapeutics during the third quarter valued at about $10,390,000. Vanguard Group Inc. increased its stake in Avalo Therapeutics by 314.9% during the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after acquiring an additional 525,696 shares during the last quarter. Millennium Management LLC increased its stake in Avalo Therapeutics by 380.2% during the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after acquiring an additional 522,548 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in shares of Avalo Therapeutics in the 4th quarter worth about $8,637,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

More Avalo Therapeutics News

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $30 price target, implying substantial upside from recent trading levels. Bank of America Securities also reaffirmed its Buy rating, providing continued analyst support. Bank of America Securities Reaffirms Buy Rating
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day days-to-cover ratio. This suggests no meaningful short-selling signal, but the reported figures appear unreliable because the entry describes the change as “NaN.”
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to a loss of $2.76 from $2.02 and its FY2027 forecast to a loss of $2.41 from $1.78. Quarterly estimates for Q3 and Q4 2026 and each quarter of 2027 were also lowered, indicating expectations for deeper or more persistent losses. HC Wainwright Cuts Avalo Therapeutics Price Target
• Negative Sentiment: The earnings outlook remains challenging: Avalo recently reported a quarterly loss that missed expectations, while analysts continue to forecast significant losses. A separate report highlighted widening losses, even as improving EPS trends may indicate a potential strategic transition. Avalo Therapeutics Widening Losses and EPS Outlook

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AVTX. Mizuho lifted their price objective on Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Citizens Jmp cut their price target on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. Piper Sandler reaffirmed an “overweight” rating and set a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Wedbush decreased their price objective on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Finally, HC Wainwright dropped their price objective on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Thirteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.10.

Insider Transactions at Avalo Therapeutics

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the completion of the sale, the insider owned 51,776 shares of the company’s stock, valued at $931,968. This trade represents a 2.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is owned by company insiders.

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX opened at $19.47 on Wednesday. Avalo Therapeutics, Inc. has a 1-year low of $8.41 and a 1-year high of $24.27. The business has a 50-day moving average of $17.45 and a 200-day moving average of $16.36. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -4.46 and a beta of 0.80.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). Research analysts expect that Avalo Therapeutics, Inc. will post -2.59 EPS for the current fiscal year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.